This podcast provides practical strategies for managing psychopharmacology side effects using the Rawlings–Thompson A-F classification system and low-slow titration techniques.
A pharmacogenomic study identifies an ANK3 gene variant as a predictive biomarker for treatment response to liafensine, a triple reuptake inhibitor, in patients with treatment-resistant depression.
This study validates a neurotransmitter-centric computational pipeline for analyzing EEG spectral power changes in patients taking psychotropic medications, offering a more mechanistic framework for understanding drug effects than traditional class-based approaches.
Centanafadine demonstrates efficacy in clinical studies for treating ADHD in both adult and pediatric populations, representing a new pharmacological option for this condition.
A recent hypothesis suggests clozapine's superior efficacy in treatment-resistant schizophrenia may be driven by muscarinic receptor agonism rather than its traditional dopaminergic profile.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Dec 01 – Jun 19)
- Consider prescribing centanafadine as a novel pharmacological option for ADHD in both adult and pediatric populations when standard therapies are insufficient.
- Utilize the new PBPK/PD model that integrates genetic polymorphisms to optimize precision dosing of clozapine for treatment-resistant schizophrenia.
- Monitor metabolic safety closely when prescribing cariprazine for affective disorders, as recent meta-analyses provide updated evidence-based data on its profile.
- Evaluate xanomeline and other cholinergic modulators as emerging efficacy options for schizophrenia, supported by recent Bayesian network meta-analysis.
- Apply the Rawlings–Thompson A-F classification system to systematically manage psychopharmacology side effects during clinical practice.
- Use low-slow titration techniques alongside the Rawlings–Thompson framework to mitigate adverse effects when initiating or adjusting psychotropic medications.
- Consider roflumilast as a potential off-label strategy to enhance memory network activity and address cognitive deficits in schizophrenia patients.
- Recognize that muscarinic receptor agonism may be a key driver of clozapine's superior efficacy in treatment-resistant schizophrenia, beyond its traditional dopaminergic profile.
- Liafensine response in treatment-resistant depression may be predicted by the presence of an ANK3 gene variant, suggesting a role for pharmacogenomic testing.
Mechanism of Action 1
A new PBPK/PD model integrates genetic polymorphisms to optimize clozapine precision dosing for treatment-resistant schizophrenia.
Journal Article 4
A pilot study suggests the PDE4 inhibitor roflumilast may enhance memory network activity in schizophrenia patients, highlighting a potential off-label strategy for treating cognitive deficits associated with the disorder.
This systematic review and meta-analysis evaluates the metabolic safety profile of cariprazine in patients with affective disorders, providing evidence-based data for clinicians prescribing this second-generation antipsychotic.
A network meta-analysis of 55 trials evaluates pharmacological and non-pharmacological interventions for managing antipsychotic-induced weight gain in schizophrenia.
A Bayesian network meta-analysis evaluates the efficacy and safety of cholinergic modulators, including xanomeline, for treating schizophrenia.
Neuroscience 1
A study examines the relationship between glutamate levels and cerebral blood flow in patients with treatment-resistant schizophrenia during clozapine therapy.